The increasing launch of effective drugs is a key factor driving theU.S. secondary hyperparathyroidism treatment market, says Fortune Business Insights in a report, titled “Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share and Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital and Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026.” The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%.
Key Players Operating in The U.S Secondary Hyperparathyroidism Treatment Market Include:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664
Emerging Guidelines By Government Authorities Will Boost Growth
The increasing government initiatives for improvising secondary hyperparathyroidism management will create growth opportunities for the secondary hyperparathyroidism treatment market. The aim of SHPT treatment is to manage the biochemical markers of bone and mineral metabolism, which are directly linked to cardiovascular events and bone fractures by extensive epidemiologic evidence. International and national organizations in the U.S. and working groups such as the National Kidney Foundation have published various clinical guidance documents to encourage best practices in managing SHPT.
Furthermore, increasing awareness about SHPT in physicians, as well as clinical specialists, have improved the treatment regimen for its management. The improvement in earlier identification and assessment of SHPT for mineral metabolism in CKD and ESRD will have a positive impact on secondary hyperparathyroidism treatment market growth. The reduction in associated complications for the management of SHPT is expected to accelerate growth of the market during the forecast period.
Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth
The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market.
Request A Sample Copy – U.S Secondary Hyperparathyroidism Treatment Market Report
The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.
Detailed Table of Content:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4.1 Prevalence of Secondary Hyperparathyroidism, 2018
4.2 Distribution of Secondary Hyperparathyroidism Patients by Treatment Type Surgery, Drugs and Others, 2018
4.3 Key Industry Developments Mergers, Acquisitions and Partnerships
4.4 Pipeline Analysis
4.5 Reimbursement Scenario
4.6 Cost Burden of Secondary Hyperparathyroidism
5.1. Market Analysis, Insights, and Forecast By Drug Class
5.1.1 Calcimimetics
5.1.2 Vitamin D Analogues
5.1.3 Phosphate Binders
5.2. Market Analysis, Insights, and Forecast By Distribution Channel
5.2.1 Hospital and Retail Pharmacies
5.2.2 Online Pharmacies
5.2.3 Others
5.3. Market Analysis, Insights, and Forecast By Region
5.3.1 West
5.3.2 Midwest
5.3.3 South
5.3.4 Northeast
6.1. Key Industry Developments
6.2. U.S. Market Share Analysis (2018)
6.3. Competition Dashboard
6.4. Comparative Analysis Major Players
6.5. Company Profiles (Overview, Products and Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
6.5.1 Teva Pharmaceutical Industries Ltd.
6.5.2 Genzyme Corporation (Sanofi)
6.5.3 AbbVie Inc.
6.5.4 Cipla Inc.
6.5.5 Dr. Reddy’s Laboratories Ltd.
6.5.6 Amgen Inc.
6.5.7 OPKO Health, Inc.
Continued…
Have Any Query? Ask Our Experts
Reasons to Purchase this Report:
KEY QUESTIONS ANSWERED:
More Trending Topics From Fortune Business Insights@
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email:sales@fortunebusinessinsights.com
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit U.S Secondary Hyperparathyroidism Treatment Market 2020 | Global Analysis, Size,Trends, Growth Insight, Key Players, Regional Outlook With Forecast To 2026